Peripheral vascular intervention devices market seen reaching $18.03 billion by 2030

The Business Research Company says the peripheral vascular intervention devices market is on a steady growth path, driven by diabetes, peripheral artery disease and wider use of minimally invasive treatments. The market is projected to rise from $11.97 billion in 2025 to $18.03 billion by 2030, with North America leading in 2025 and Asia-Pacific expected to grow fastest.

Why it matters: - The peripheral vascular intervention devices market is tied to treatment for blood vessel disease outside the heart and brain, where faster recovery and lower procedural risk can improve care. - Rising demand is being driven by diabetes, peripheral artery disease and broader use of minimally invasive vascular procedures. - The market’s growth points to expanding use of catheter-based tools in hospitals, outpatient centers and ambulatory settings.

What happened: - The Business Research Company published its Peripheral Vascular Intervention Devices Market Report 2026, covering market size, trends and a global forecast through 2035. - The market is projected to grow from $11.97 billion in 2025 to $12.97 billion in 2026, implying 8.4% growth. - The report forecasts the market will reach $18.03 billion by 2030, at a 8.6% compound annual growth rate. - North America led the market by size in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - A free sample of the report is available here. - The full report is available here.

The details: - Peripheral vascular intervention devices are used to diagnose and treat narrowed or blocked arteries and veins outside the heart and brain. - These devices support minimally invasive procedures for peripheral arterial and venous disorders. - The report says growth during the historic period was fueled by higher peripheral artery disease rates, more minimally invasive surgery, an aging population, more hospital catheterization labs and greater awareness of early diagnosis. - Future growth is expected to be supported by image-guided interventions, wider use of drug-coated and bioresorbable devices, more outpatient and ambulatory vascular care, personalized vascular disease management and ongoing catheter-based innovation. - The report highlights AI-driven imaging, drug-eluting and bioabsorbable devices, atherectomy and plaque-modification tools, and catheter-based vascular management as major trends. - The market analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - Diabetes is a major demand driver because vascular damage from the disease can lead to peripheral artery disease and critical limb ischemia, both of which often require endovascular treatment. - The NHS said in June 2024 that 549,000 additional people in England were identified as being at risk of type 2 diabetes in 2023, bringing total registered non-diabetic hyperglycemia cases to 3,615,330. - That total was up nearly 20% from 3,065,825 in 2022, underscoring the pressure from rising diabetes prevalence. - The regional split suggests the market is mature in North America but still has faster growth runway in Asia-Pacific. - The report’s focus on AI and bioresorbable technologies signals a shift toward more precise and less invasive vascular care.

What's next: - The market is expected to keep expanding as demand rises for image-guided, minimally invasive and personalized vascular treatments. - Adoption should increase for drug-eluting, bioabsorbable and catheter-based technologies as clinical practice evolves. - The report’s longer-range forecast through 2035 gives buyers and suppliers a roadmap for device demand and regional opportunities. - The company also offers market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspots infographics and updated graphics and tables in its 2026 reports.

The bottom line: - Peripheral vascular intervention devices are moving from niche tools to a larger, faster-growing part of vascular care as diabetes and vascular disease cases climb globally.